Stock events for Sensus Healthcare, Inc. (SRTS)
Over the past six months, Sensus Healthcare's stock experienced a 52-week high of $5.92 and a 52-week low of $3.03. In February 2026, the company reported its Fourth Quarter and Full Year 2025 financial results, revealing a profit swing to a loss and a decline in SRTS shares, although dedicated CPT codes for SRT were highlighted. In November 2025, Sensus Healthcare reported its Third Quarter 2025 financial results, noting decreased revenues but a sequential increase in Fair Deal Agreement (FDA) treatment volume and finalized new CPT codes for SRT.
Demand Seasonality affecting Sensus Healthcare, Inc.’s stock price
Sensus Healthcare's products and services exhibit some demand seasonality, with the company expecting higher revenue in the second half of the year compared to the first half. Management anticipated Q2 revenue to be higher than Q1 revenue. Skin Cancer Awareness Month in May suggests a potential seasonal focus, and the company noted 'various seasonal event-driven and opportunistic headwinds' in Q1 2025.
Overview of Sensus Healthcare, Inc.’s business
Sensus Healthcare, Inc. is a medical device company specializing in non-invasive, low-energy Superficial Radiation Therapy (SRT) systems for oncological and non-oncological skin conditions. Their major products include the SRT-100™, SRT-100+™, and SRT-100 Vision™ systems, along with services like the Sentinel program and a Transdermal Infusion system. The company also distributes laser devices for aesthetic applications and generates revenue through capital equipment sales and a recurring revenue program.
SRTS’s Geographic footprint
Sensus Healthcare, Inc. has an expanding international presence, including shipments to China, but generates a substantial portion of its revenue from the United States. The company is headquartered in Boca Raton, Florida, and had 955 SRT units installed in 21 countries as of December 31, 2025.
SRTS Corporate Image Assessment
Sensus Healthcare has maintained a positive brand reputation over the past year. The company was named to TIME's list of America's Growth Leaders of 2026. A study published in Dermatologic Therapy demonstrated the efficacy of Sensus' SRT combined with punch excision to treat keloids. The Centers for Medicare & Medicaid Services (CMS) finalized new CPT codes for SRT in Q4 2025.
Ownership
Sensus Healthcare, Inc.'s ownership is a mix of individual investors, institutional investors, and insiders. Individual investors hold a significant portion, with institutions owning approximately 32% of the company. Major institutional shareholders include Vanguard Group Inc and Pacific Ridge Capital Partners, LLC. Joseph Sardano, Co-Founder, Chairman, and CEO, is the largest individual shareholder, owning 7.31% of shares outstanding.
